Quinazoline compounds

Patent metadata

Field	Value
Publication number	US-10548898-B2
Application number	US-201916239578-A
Country	US
Kind code	B2
Filing date	Jan 4, 2019
Priority date	Dec 24, 2014
Publication date	Feb 4, 2020
Grant date	Feb 4, 2020

Abstract

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

First claim

What is claimed is:

1. A compound of formula:

or a tautomer or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 , further comprising one, two, three, or four additional therapeutic agents.

4. The pharmaceutical composition of claim 3 , wherein the therapeutic agent is independently selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating HIV, and combinations thereof.

5. A method for treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof.

6. A method for treating an HIV infection in a subject comprising administering to the subject in need thereof a compound of claim 1 , or a tautomer or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, and other drugs for treating or preventing HIV, and combinations thereof.

Assignees

• Gilead Sciences Inc
• Inst Of Organic Chemistry And Biochemistry Of The As Cr V V I

Inventors

• Baszczynski Ondrej
• Dejmek Milan
• Hu Yunfeng Eric
• Jansa Petr
• Lansdon Eric
• Mackman Richard L
• Simon Petr

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D239/95

  with hetero atoms directly attached in positions 2 and 4 · CPC title